PURPOSE: To determine the contribution of total body irradiation (TBI) to late sequelae in children treated with high-dose chemotherapy and autologous bone marrow transplantation for Stage IV neuroblastoma. PATIENTS AND METHODS: We compared two populations that were similar with regard to age, stage, pre-autologous bone marrow transplantation chemotherapy (CT) regimen, period of treatment, and follow-up (12 years). The TBI group (n = 32) received TBI as part of the megatherapy procedure (1982-1993), whereas the CT group (n = 30) received conditioning without TBI (1985-1992). Analysis 12 years later focused on growth, weight and corpulence (body mass index) delay; hormonal deficiencies; liver, kidney, heart, ear, eye, and dental sequelae; school performance; and the incidence of secondary tumors. RESULTS: Impact of TBI was most marked in relation to growth and weight delay, although the mean delay was not severe, probably because of treatment with growth hormones. Other consequences of TBI were thyroid insufficiency, cataracts, and a high incidence of secondary tumors. Hearing loss and dental agenesis were more prominent in the group treated with CT alone. No differences were observed in school performance. CONCLUSION: The most frequent side effects of TBI were cataracts, thyroid insufficiency, and growth delay, but more worrying is the risk of secondary tumors. Because of the young mean age of patients and the toxicity of TBI regimens without any survival advantage, regimens without TBI are preferable in the management of Stage IV neuroblastoma.
PURPOSE: To determine the contribution of total body irradiation (TBI) to late sequelae in children treated with high-dose chemotherapy and autologous bone marrow transplantation for Stage IV neuroblastoma. PATIENTS AND METHODS: We compared two populations that were similar with regard to age, stage, pre-autologous bone marrow transplantation chemotherapy (CT) regimen, period of treatment, and follow-up (12 years). The TBI group (n = 32) received TBI as part of the megatherapy procedure (1982-1993), whereas the CT group (n = 30) received conditioning without TBI (1985-1992). Analysis 12 years later focused on growth, weight and corpulence (body mass index) delay; hormonal deficiencies; liver, kidney, heart, ear, eye, and dental sequelae; school performance; and the incidence of secondary tumors. RESULTS: Impact of TBI was most marked in relation to growth and weight delay, although the mean delay was not severe, probably because of treatment with growth hormones. Other consequences of TBI were thyroid insufficiency, cataracts, and a high incidence of secondary tumors. Hearing loss and dental agenesis were more prominent in the group treated with CT alone. No differences were observed in school performance. CONCLUSION: The most frequent side effects of TBI were cataracts, thyroid insufficiency, and growth delay, but more worrying is the risk of secondary tumors. Because of the young mean age of patients and the toxicity of TBI regimens without any survival advantage, regimens without TBI are preferable in the management of Stage IV neuroblastoma.
Authors: Brian H Kushner; Stephen S Roberts; Danielle N Friedman; Deborah Kuk; Irina Ostrovnaya; Shakeel Modak; Kim Kramer; Ellen M Basu; Nai-Kong V Cheung Journal: Cancer Date: 2015-02-27 Impact factor: 6.860
Authors: Sara M Federico; Heather B Allewelt; Sheri L Spunt; Melissa M Hudson; Jianrong Wu; Catherine A Billups; Jesse Jenkins; Victor M Santana; Wayne L Furman; Lisa M McGregor Journal: J Pediatr Hematol Oncol Date: 2015-01 Impact factor: 1.289
Authors: Ki Woong Sung; Hyo Seop Ahn; Bin Cho; Yong-Mook Choi; Nack Gyun Chung; Tai Ju Hwang; Ho Joon Im; Dae Chul Jeong; Hyoung Jin Kang; Hong Hoe Koo; Hoon Kook; Hack Ki Kim; Chuhl Joo Lyu; Jong Jin Seo; Hee Young Shin; Keon Hee Yoo; Sung Chul Won; Kun Soo Lee Journal: J Korean Med Sci Date: 2010-04-21 Impact factor: 2.153
Authors: Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca Journal: J Clin Oncol Date: 2009-01-26 Impact factor: 44.544
Authors: Kelly E Huibregtse; Kieuhoa T Vo; Steven G DuBois; Stephanie Fetzko; John Neuhaus; Vandana Batra; John M Maris; Brian Weiss; Araz Marachelian; Greg A Yanik; Katherine K Matthay Journal: Eur J Cancer Date: 2016-08-27 Impact factor: 9.162
Authors: Gabriel Chodick; Ruth A Kleinerman; Marilyn Stovall; David H Abramson; Johanna M Seddon; Susan A Smith; Margaret A Tucker Journal: Arch Ophthalmol Date: 2009-11
Authors: Sara M Federico; Samuel L Brady; Alberto Pappo; Jianrong Wu; Shenghua Mao; Valerie J McPherson; Alison Young; Wayne L Furman; Robert Kaufman; Sue Kaste Journal: Pediatr Blood Cancer Date: 2015-01-13 Impact factor: 3.167
Authors: Jung Min Suh; Keon Hee Yoo; Ki Woong Sung; Ju Youn Kim; Eun Joo Cho; Hong Hoe Koo; Suk Koo Lee; Jhingook Kim; Do Hoon Lim; Yeon Lim Suh; Dae Won Kim Journal: J Korean Med Sci Date: 2009-07-29 Impact factor: 2.153